Lung Cancer - Radiation Therapy

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold ContributorGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors do not report synergic side...

Podcast

The Atrium: Neoadjuvant Chemoimmunotherapy

September 29, 2026 | Alice Copperwheat…

In this episode of The Atrium, host Alice Copperwheat speaks with Jessica Donington, Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago, Illinois,...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold ContributorGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Personalized Magnetic Tentacles for Targeted Photothermal Cancer Therapy in Peripheral Lungs

October 12, 2023 | Jason TrevisBronze Contributor

Lung cancer has the highest worldwide cancer mortality rate. Early non-small cell lung cancer accounts for 84 percent of cases, with curative surgical intervention being the standard treatment. The authors...

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindGold Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part...

JANS Article

Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy

December 28, 2015 | Lisa BrownBronze Contributor

The goal of this study was to present the changes in pulmonary function after SBRT in 127 patients with clinical stage I NSCLC or a single lung metastasis. These patients...

JANS Article

Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy (SBRT).

September 20, 2015 | Philip McElnay

A large retrospective study comparing 117618 patients from the National Cancer Database with Stage I NSCLC. 111731 received surgery, 5887 received SBRT. In a propensity managed comparison, those undergoing surgery...

JANS Article

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

September 12, 2015 | Mark FergusonGold Contributor

This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts...

JANS Article

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized controlled trials – Part 1 of 9

August 20, 2015 | Lisa BrownBronze Contributor

Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial)....

JANS Article

SABR in early operable lung cancer: time for evidence – Part 2 of 9

August 20, 2015 | Lisa BrownBronze Contributor

This is an invited commentary on the article by Chang and colleagues (Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised...

JANS Article

Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? – Part 3 of 9

August 20, 2015 | Lisa BrownBronze Contributor

This expert opinion editorial is published in JTCVS in response to the article by Chang and colleagues. Meyers and colleagues begin by emphasizing that a large randomized controlled trial (RCT)...

JANS Article

Surgery versus SABR for resectable non-small-cell lung cancer – Part 4 of 9

August 20, 2015 | Lisa BrownBronze Contributor

This is a letter in response to the article by Chang and colleagues. The authors point out that only 58 patients were enrolled from 38 centers over 66.3 months, and...

JANS Article

Surgery versus SABR for resectable non-small-cell lung cancer – Part 5 of 9

August 20, 2015 | Lisa BrownBronze Contributor

This is a letter in response to the article by Chang and colleagues. The authors focus on two key points: the difference in 3-year survival between the two treatment groups...

LOAD MORE
ADVERTISE ON CTSNET